Rapport Therapeutics, Inc. Common Stock (RAPP) 10-Year Financial Performance & Capital Metrics

RAPP • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutRapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.Show more

Revenue $0
EBITDA -$82M -128.0%
Net Income -$78M -125.1%
EPS (Diluted) -0.38 -100.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -55.97%
ROIC -79.64%
Debt/Equity 0.00
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 90 (top 10%)

✗Weaknesses

✗Shares diluted 14.7% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 18.2x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-35.99%

EPS CAGR

10Y-

5Y-

3Y-

TTM-346.33%

ROCE

10Y Avg-37.43%

5Y Avg-37.43%

3Y Avg-37.43%

Latest-36.69%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0
Revenue Growth %	-	-	-
Cost of Goods Sold+	15K	112K	839K
COGS % of Revenue	-	-	-
Gross Profit+	-15K	-112K	-839K
Gross Margin %	-	-	-
Gross Profit Growth %	-	-6.47%	-6.49%
Operating Expenses+	10.35M	36.07M	82.22M
OpEx % of Revenue	-	-	-
Selling, General & Admin	1.37M	8.07M	22.12M
SG&A % of Revenue	-	-	-
Research & Development	9.12M	28M	60.94M
R&D % of Revenue	-	-	-
Other Operating Expenses	-128.82K	0	-839K
Operating Income+	-10.37M	-36.18M	-83.06M
Operating Margin %	-	-	-
Operating Income Growth %	-	-2.49%	-1.3%
EBITDA+	-10.35M	-36.07M	-82.22M
EBITDA Margin %	-	-	-
EBITDA Growth %	-	-2.48%	-1.28%
D&A (Non-Cash Add-back)	15K	112K	839K
EBIT	-10.37M	-34.78M	-78.31M
Net Interest Income+	-285K	2.53M	12.14M
Interest Income	0	2.53M	12.14M
Interest Expense	285K	0	0
Other Income/Expense	-285K	1.4M	4.75M
Pretax Income+	-10.65M	-34.78M	-78.31M
Pretax Margin %	-	-	-
Income Tax+	0	10K	0
Effective Tax Rate %	1%	1%	1%
Net Income+	-10.65M	-34.79M	-78.31M
Net Margin %	-	-	-
Net Income Growth %	-	-2.27%	-1.25%
Net Income (Continuing)	-10.65M	-34.79M	-78.31M
Discontinued Operations	0	0	0
Minority Interest	0	0	0
EPS (Diluted)+	-0.05	-0.19	-0.38
EPS Growth %	-	-2.58%	-1%
EPS (Basic)	-0.05	-0.19	-0.38
Diluted Shares Outstanding	201.17M	180.79M	207.38M
Basic Shares Outstanding	201.17M	180.79M	207.38M
Dividend Payout Ratio	-	-	-

Balance Sheet

	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	31.27M	150.87M	309.8M
Cash & Short-Term Investments	31.16M	147.48M	305.28M
Cash Only	31.16M	70.17M	56.8M
Short-Term Investments	0	77.31M	248.47M
Accounts Receivable	0	0	0
Days Sales Outstanding	-	-	-
Inventory	0	0	0
Days Inventory Outstanding	-	-	-
Other Current Assets	0	3.39M	4.52M
Total Non-Current Assets+	335K	4.55M	5.13M
Property, Plant & Equipment	335K	4M	4.97M
Fixed Asset Turnover	-	-	-
Goodwill	0	0	0
Intangible Assets	0	0	0
Long-Term Investments	0	0	0
Other Non-Current Assets	0	551K	160K
Total Assets+	31.6M	155.42M	314.93M
Asset Turnover	-	-	-
Asset Growth %	-	3.92%	1.03%
Total Current Liabilities+	1.66M	8.8M	8.77M
Accounts Payable	1.45M	2.5M	1.95M
Days Payables Outstanding	35.28K	8.15K	850.07
Short-Term Debt	0	0	0
Deferred Revenue (Current)	0	0	0
Other Current Liabilities	0	2.41M	3.71M
Current Ratio	18.80x	17.14x	35.34x
Quick Ratio	18.80x	17.14x	35.34x
Cash Conversion Cycle	-	-	-
Total Non-Current Liabilities+	10.44M	172.25M	739K
Long-Term Debt	10.44M	0	0
Capital Lease Obligations	0	1.48M	739K
Deferred Tax Liabilities	0	0	0
Other Non-Current Liabilities	0	170.78M	0
Total Liabilities	12.1M	181.06M	9.51M
Total Debt+	10.44M	2.15M	1.48M
Net Debt	-20.72M	-68.02M	-55.33M
Debt / Equity	0.53x	-	0.00x
Debt / EBITDA	-	-	-
Net Debt / EBITDA	-	-	-
Interest Coverage	-36.38x	-	-
Total Equity+	19.5M	-25.63M	305.43M
Equity Growth %	-	-2.31%	12.91%
Book Value per Share	0.10	-0.14	1.47
Total Shareholders' Equity	19.5M	-25.63M	305.43M
Common Stock	31K	4K	37K
Retained Earnings	-10.65M	-45.44M	-123.75M
Treasury Stock	0	0	0
Accumulated OCI	0	4K	-522K
Minority Interest	0	0	0

Cash Flow

	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.24M	-27.18M	-64.83M
Operating CF Margin %	-	-	-
Operating CF Growth %	-	-7.38%	-1.39%
Net Income	-10.65M	-34.79M	-78.31M
Depreciation & Amortization	16.36K	112K	839K
Stock-Based Compensation	609.82K	3.52M	10.23M
Deferred Taxes	0	0	0
Other Non-Cash Items	5.3M	1.32M	4.82M
Working Capital Changes	1.49M	2.65M	-2.42M
Change in Receivables	0	0	0
Change in Inventory	0	0	0
Change in Payables	0	856K	-346K
Cash from Investing+	-5.28M	-78.86M	-170.14M
Capital Expenditures	-284K	-1.64M	-2.4M
CapEx % of Revenue	-	-	-
Acquisitions	-	-	-
Investments	-	-	-
Other Investing	-5M	0	3.21M
Cash from Financing+	39.69M	145.14M	221.63M
Debt Issued (Net)	-	-	-
Equity Issued (Net)	-	-	-
Dividends Paid	0	0	0
Share Repurchases	-	-	-
Other Financing	0	-134K	7K
Net Change in Cash	-	-	-
Free Cash Flow+	-3.53M	-28.82M	-67.23M
FCF Margin %	-	-	-
FCF Growth %	-	-7.17%	-1.33%
FCF per Share	-0.02	-0.16	-0.32
FCF Conversion (FCF/Net Income)	0.30x	0.78x	0.83x
Interest Paid	0	0	0
Taxes Paid	0	0	0

Key Ratios

Metric	2022	2023	2024
Return on Equity (ROE)	-54.61%	-	-55.97%
Return on Invested Capital (ROIC)	-	-	-79.64%
Debt / Equity	0.53x	-	0.00x
Interest Coverage	-36.38x	-	-
FCF Conversion	0.30x	0.78x	0.83x

Frequently Asked Questions

Growth & Financials

Rapport Therapeutics, Inc. Common Stock (RAPP) grew revenue by 0.0% over the past year. Growth has been modest.

Rapport Therapeutics, Inc. Common Stock (RAPP) reported a net loss of $97.7M for fiscal year 2024.

Dividend & Returns

Rapport Therapeutics, Inc. Common Stock (RAPP) has a return on equity (ROE) of -56.0%. Negative ROE indicates the company is unprofitable.

Rapport Therapeutics, Inc. Common Stock (RAPP) had negative free cash flow of $77.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener